Abstract Disorders of fatty acid oxidation are rare but can be fatal. Hypoglycaemia with acidosis is a cardinal feature. Cases may present during early childhood or can be delayed into adolescence or beyond. We present a case of multiple acylcoenzyme A dehydrogenase deficiency (MADD), an extremely rare disorder of fatty acid oxidation. Our 20-year-old patient presented with cardiovascular collapse, raised anion gap metabolic acidosis and non-ketotic hypoglycaemia. She subsequently developed multi-organ failure and sadly died. She had a previous diagnosis of cyclic vomiting syndrome (CVS) for more than 10 years, warranting frequent hospital admissions. The association between CVS and MADD has been made before though the exact relationship is unclear. All patients with persistent severe CVS should have metabolic investigations to exclude disorders of fatty acid oxidation. In case of non-ketotic hypoglycaemia with acidosis, the patient should be urgently referred to a specialist in metabolic diseases. All practitioners should be aware of these rare disorders as a cause of unexplained acidosis.
Introduction
Fatty acid oxidation disorders are rare but are being more frequently diagnosed with increasing sophistication and accessibility of detection methods. These disorders usually present in childhood but may present later in life in those with less severe phenotypes. We present a young critically ill patient with multiple acyl-coenzyme A dehydrogenase deficiency (MADD). The patient had a background history of cyclical vomiting syndrome (CVS).
Fatty acid oxidation disorders are an unusual cause of acidaemia in the critically ill but should be considered in the differential diagnosis of unexplained acidosis. Due to their relatively rare incidence and diversity of presentation, these diseases may be missed.
Case history
A 20-year-old female was presented to the Emergency Department with a 1-week history of sore throat, nausea, right flank pain, lethargy and anorexia. Background history was notable for CVS, diagnosed 12 years previously, and chronic fatigue commencing in her teens.
Examination revealed dehydration, including sinus tachycardia of 140 bpm, and blood pressure was 116/ 67 mmHg. The abdomen was soft with slight tenderness in the right hypochondrium. She was initially treated with intravenous 0.9 % saline and antiemetic.
Ten hours later, she had a witnessed cardiac arrest with an initial rhythm of ventricular fibrillation. She was successfully resuscitated, with a return of spontaneous circulation after 16 min.
Pre-arrest investigations were notable only for a WCC of 16×10 9 . Post resuscitation, she had acidaemia with a pH of 7.18. There was metabolic acidosis with an elevated anion gap of 22 and a lactate level of 6.1. There was marked hypoglycaemia with blood glucose of 1.3 mmol/L. Of note, ketone screen was negative.
Organ support was commenced including mechanical ventilation, renal replacement therapy and vasopressor infusions. Persistent hypoglycaemia required boluses of 50 % dextrose. She was treated empirically with broad-spectrum antimicrobials. No source of sepsis was found, despite multiple investigations. Abdominal ultrasound and CT of the abdomen showed fatty infiltration of the liver with ascites. Liver function tests were abnormal and continued to deteriorate. Throughout her critical illness, she had a profound metabolic acidosis, which did not respond to any treatment. Vasopressor therapy rapidly escalated despite massive fluid resuscitation. Unfortunately, 72 h after presentation, fulminant multi-organ failure had evolved, refractory to aggressive treatment, and the patient died.
Post-mortem results
Post-mortem examination was consistent with multi-organ failure. Post-mortem findings were significant in pointing towards an underlying disorder of fatty acid metabolism, with evidence of abnormal fat storage seen in the skeletal muscle, liver and cardiac muscle. There was also an unusual pattern of vacuolar change in the granular layer of the cerebellum (Fig. 1 ). This cerebellar change was diagnostic. Skeletal muscle fibres were noted to hold excess sarcoplasmic fat with multiple intra-sarcoplasmic vacuoles in type 1 fibres with atrophy. There was diffuse, bi-hemispheric cerebral oedema.
Abnormal lipid storage involving the skeletal muscle, heart muscle, liver and cerebellum suggested a diagnosis of MADD. Unfortunately, no urine or blood samples were available for biochemical analysis. The patient's original newborn screening dried blood spot was analysed for acylcarnitine species but was non-diagnostic. Molecular analysis of the ETFDH gene from the DNA extracted from the paraffinembedded muscle and the newborn blood spot found compound heterozygosity for the following pathogenic mutations: c.51_52ins (p.ala18cysfsX5), a novel frameshift mutation and c.1367C>T (p.pro456leu), a previously reported pathogenic missense mutation, thus confirming a diagnosis of MADD.
Background history (obtained from her parents in later months)
The patient was born at term, and there were no neonatal concerns. At the age of 6 months and again at 12 months, she was admitted to the hospital acutely unwell, limp and lifeless; she recovered fully following treatment with IV fluids and antibiotics. No infection source was found on either occasion.
She was diagnosed with CVS at age 9 years and had episodic vomiting once every 6 weeks or so. For some of these episodes, she required hospital admission for treatment with intravenous dextrose. She had documented ketones in her urine during some of these admissions; only on one occasion was mild hypoglycaemia noted. In her late teens, she had a number of episodes of collapse, and she may have had one seizure. She was reported to drink much high sugar drinks (Lucozade ®). In the weeks before this presentation, she had been unusually fatigued, and had neck weakness and exercise intolerance. She had been recently transferred from the local paediatric service to an adult physician for monitoring of her symptoms, though these had been attributed to CVS.
Informed consent has been obtained from her parents for publication of her case. Local Ethics Committee Board approval was sought and waived.
Discussion
Raised anion gap metabolic acidosis is caused by the addition of endogenous or exogenous acids to the system. Common causes in critically ill patients are production of lactic acids, keto acids or renal failure, or the addition of exogenous acids (salicylates, methanol, ethylene glycol). In this case, an initial toxicology screen was negative for alcohol and salicylates. Ethylene glycol or methanol poisoning was out-ruled. Renal replacement therapy was commenced for treatment of acidosis, not renal failure, and urinary ketones were not present. Though lactate was initially elevated, it was cleared by CVVH, and the acidosis was felt as a consequence of tissue hypoxia rather than a cause.
The clinical course of our patient was rapidly progressive, and fulminant multi-organ failure supervened while investigations were ongoing. A first presentation of this disorder in adulthood is extremely rare, but metabolic disease should be considered in all cases of refractory hypoglycaemia with acidosis, ketotic or non-ketotic. Urinary organic acid analysis and blood acylcarnitine profile may yield the diagnosis during an episode of decompensation. The hypoglycaemia in fatty acid oxidation disorders is most easily explained by the inability of affected patients to use fatty acids as fuel, which normally occurs during fasting via dehydrogenases. In MADD, multiple different dehydrogenase reactions in the mitochondrial electron chain are affected with at least 12 different enzymes being implicated. Many patients with MADD have been shown to have mutations in ETFA, ETFB or ETFDH [8] genes, which code for flavoprotein dehydrogenases.
MADD (OMIM number 231680, also known as glutaric aciduria type II) is an autosomal recessive, mitochondrial organic acid disorder. There are three distinct phenotypes described: types 1 and 2 occur during infancy and are usually fatal [1] . Type 3 is typically characterised by myopathy together with hepatic insufficiency with a later onset. There are acute episodes with increased weakness, vomiting, hypoglycaemia and acidosis. It has a heterogeneous manifestation but is usually diagnosed before the age of 15 years. It has been found in some series to be responsive to riboflavin and ubiquinone (coenzyme Q10) and L-carnitine treatments [8] . In all forms, the pathophysiology of this disorder involves the development of episodic hypoketotic hypoglycaemia provoked by catabolic stress. Clinically, episodes may present as coma, multiple organ failure or muscle weakness. A high mortality has been reported.
Due to its extreme rarity, the exact incidence of MADD is unknown. It may have a higher incidence in Asia, where many of the case reports originate from. Genetic analysis suggests that the majority of Chinese cases of lipid storage myopathy are caused by ETFDH gene mutations [4] . Coenzyme Q10 or ubiquinone deficiencies may be allelic with MADD [3] .
Traditionally, diagnosis is by gas chromatographic/mass spectrometric analysis of urinary organic acids or by neonatal blood spot analysis of acylcarnitine species. The adult forms may be missed in the well newborn. Mutation analysis is a superior tool for specific diagnosis. This case was positive for two heterogeneous mutations of the ETFDH gene that were both pathogenic. The c.51_52ins mutation causes a frameshift, and a subsequent premature termination would therefore be expected to be a severe mutation. The missense c.1367C > T mutation has been described in patients with MADD and is associated with a milder phenotype (MADD type 3) and riboflavin responsiveness [8] . The patient's parents have both been confirmed as carriers. DNA extracted from the paraffin-embedded muscle and the patient's more than 20-year-old original newborn screening card was used for the genetic analysis.
The association between CVS and MADD has been made before [9] , though whether this represents a true association or whether the very rare MADD is inadvertently diagnosed as the more common CVS is uncertain (Irish incidence is 3.15 cases per 100,000 children [2] ).
One study [5] that was looking at alternative diagnoses presenting as CVS in 225 cases found that 88 % were in keeping with idiopathic cyclical vomiting. In this case series one patient (0.44 %) was subsequently diagnosed with a fatty acid oxidation defect (very long chain acyl-CoA dehydrogenase deficiency). Interestingly, some patients with CVS may respond to treatment with L-carnitine [7, 10] which is a well-documented treatment for MADD [6] . One study [8] of 15 patients with riboflavin responsive MADD, all of whom had an ETFDH mutation, demonstrated that 5 patients also had CVS.
As the diagnosis and therapy of MADD is complex, its management should be overseen by a metabolic disease specialist. Suspected cases should have analysis of plasma acylcarnitines and urinary organic acids, followed by ETFDH gene sequencing, where appropriate. The investigating physician must however be aware that results may have a low sensitivity and so should be repeated during physiological stress. Disorders of fatty acid oxidation should be suspected in CVS, and we recommend metabolic investigations in all children and young adults with persistent severe CVS. Non-ketotic hypoglycaemia with acidosis should prompt urgent discussion with the local metabolic service and initiation of investigations and treatments as such findings are the cardinal features of decompensated MADD. Early diagnosis is important as prophylactic dietary treatments and emergency sick-day guidelines may prevent life-threatening metabolic crises [6] . Genetic counselling is essential for affected families. Patients diagnosed acutely with MADD should be treated with riboflavin, carnitine and coenzyme Q10 supplementation, and a low-fat lowprotein diet. Patients known to have MADD who decompensate should have similar supplementation, while organ support, if necessary, is ongoing.
